CONMED Corporation
NYSE:CNMDMedical - Devices
+$0.24 today
- Market cap
- $1.43B
- Beta
- 0.92
- P/E (TTM)
- 18.0
- EPS (TTM)
- $1.79
- Dividend yield
- 1.24%
Volume 0.36M
Average 0.45M
CNMD Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
CONMED CorporationNYSE: CNMD
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $22.55M (cash outflow) fell 20.6% year over year, behind the -20.0% change in trailing-twelve-month financing cash flow. Sequentially, it fell 39.6% from the prior quarter.
Context
- Financing cash flow amounted to 9.9% of revenue in FY2025, down 1.7 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -20.6% toward the trailing-twelve-month pace of -20.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (135.82M) USD
- Year-over-year change
- +10.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (135.82M) | +10.1% |
| FY2024 | 2024-12-31 | (151M) | -36.7% |
| FY2023 | 2023-12-31 | (110.43M) | -149.1% |
| FY2022 | 2022-12-31 | 225M | +321.6% |
| FY2021 | 2021-12-31 | (101.55M) | — |
Financing Cash Flow vs competitors
How CNMD compares with its peers on the latest reported figures
- CNMD's LTM Mar 2026 financing cash flow of $129.98M is the 5th largest of the 11 companies compared; the peer median is $37.18M.
- Its year-over-year change of -20.0% is the 4th highest of 11, against a peer median of -54.1%.
- Financing cash flow amounts to 9.5% of revenue for CNMD, versus a peer median of 18.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $456.76M | -579.0% | — | 67.7% | |
| LTM Jan 2026 | $361.98M | +183.3% | — | 432.4% | |
| LTM Apr 2026 | $193.59M | -34.7% | +66.0% | 6.8% | |
| LTM Mar 2026 | $165.06M | +31.3% | -31.7% | 249.7% | |
| LTM Mar 2026 | $129.98M | -20.0% | — | 9.5% | |
| LTM Sep 2026 | $119.5M | +1145.9% | -47.8% | 19.2% | |
| LTM Mar 2026 | $66.66M | -82.6% | +45.3% | 17.8% | |
| LTM Jun 2026 | $55.35M | -144.5% | +31.0% | 8.8% | |
| LTM Sep 2026 | $28.87M | -73.5% | -26.1% | 10.9% | |
| LTM Mar 2026 | $21.92M | -24.9% | +64.3% | 45.2% | |
| LTM Aug 2026 | $19.01M | -81.4% | -5.6% | 2.2% | |
| Peer median (excluding CNMD) | $37.18M | -54.1% | +12.7% | 18.5% | |
Competitors are the stored peer set for CNMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 62.54M | (80.58M) | 64.46M | 132.42M | 47.06M |
| Depreciation & Amortization | 70.74M | 69.52M | 51.4M | 51.31M | 74.28M |
| Deferred Income Tax | 3.01M | (6.04M) | 700K | 12.2M | 3.52M |
| Stock-Based Compensation | 16.34M | 21.73M | 24.26M | 25.56M | 28.32M |
| Change in Working Capital | (55.7M) | (90.7M) | (39.58M) | (39.72M) | (11.45M) |
| Accounts Receivables | (9.16M) | (5.2M) | (47.07M) | (1.62M) | (2.36M) |
| Inventory | (37.81M) | (78.56M) | 14.07M | (31.63M) | (6.73M) |
| Accounts Payables | 4.89M | 13.3M | 14.85M | 14.71M | (9.75M) |
| Other Working Capital | (13.62M) | (20.23M) | (21.43M) | (21.19M) | 7.39M |
| Other Non-Cash Items | 14.84M | 119.44M | 24.11M | (14.8M) | 28.96M |
| Operating Cash Flow | 111.77M | 33.37M | 125.35M | 166.97M | 170.69M |
| Capital Expenditures | (14.87M) | (21.79M) | (19.03M) | (13.08M) | (19.81M) |
| Acquisitions (Net) | 0 | (227.74M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1M) | 0 | (1.15M) |
| Investing Cash Flow | (14.87M) | (249.53M) | (20.03M) | (13.08M) | (20.96M) |
| Debt Repayment | (81.24M) | 362.02M | (88M) | (72M) | (74.59M) |
| Common Stock Issued | 0 | 72M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (72M) | 0 | 0 | 0 |
| Dividends Paid | (23.26M) | (23.96M) | (24.5M) | (24.65M) | (24.75M) |
| Other Financing Activities | 2.95M | (113.06M) | 2.07M | (54.35M) | (36.49M) |
| Financing Cash Flow | (101.55M) | 225M | (110.43M) | (151M) | (135.82M) |
| Effect of Forex Changes | (1.87M) | (741K) | 470K | (2.72M) | 2.45M |
| Net Change in Cash | (6.51M) | 8.1M | (4.65M) | 163K | 16.36M |
| Free Cash Flow | 96.9M | 11.58M | 106.32M | 153.88M | 150.88M |
CONMED Corporation
NYSE:CNMD
Intrinsic Alpha fair value
Locked
Current Price
$48.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.